Gradual ramp-up of drug expected through FY22, with US revenues of $25 m; FY22e EPS down 1%; ‘Buy’ retained with…
Gradual ramp-up of drug expected through FY22, with US revenues of $25 m; FY22e EPS down 1%; ‘Buy’ retained with…
A bottom-up stock selection approach recommended in SMID; FY22/23e PAT growth estimated at 50+/23% y-o-y
Offsetting factors likely to limit impact on margins; FY22/23e EPS down 4-5%; TP revised to Rs 2,650 from Rs 2,780;…
State-wise two-wheeler (2W) registrations show that the urban-centric states have started to witness relatively better demand trends than the rural-centric…
We were positively surprised at Tughlakabad (TKD) seeing limited volume loss, despite the 10-12% realisation hike effective 6 Dec 2020.
Mgmt is optimistic about a rebound in premiums; overlap with LIC’s base needs to be watched; Buy retained with revised…
Jio may sell capacity given spectrum deals; Bharti eyes share gain; ‘Hold’ retained on Bharti with TP of Rs 590
HDFC Life has been looking to expand its agency force and also increase their contribution to premiums from 12-13% in…
The recent quarters have seen a series of initiatives beyond ‘Domino’s’, including FMCG, Biryani, Hong’s Kitchen ramp-up and 10.8% stake…
After four qtrs of YoY sales decline, FNXC saw a sharp recovery (+18%) in Q3. Volumes across most categories improved,…
Net debt was down 11% q-o-q; outlook is strong; FY22e EPS up 18%; TP raised to Rs 900 from Rs…
SBI’s 3QFY21 profit of Rs52bn (-7% YoY) was ahead of estimates, led by lower credit costs.
The two key positives were strong disbursement growth of 26% and largely stable asset quality – collections 98%, restructuring 1%,…
Downturns have seen L&T gain disproportionate market share; upturn beginning augurs well for margins. L&T’s E&C revenue and ebitda rose…
Marico has further taken up prices (in Parachute) which should help, although the management expects a correction in copra prices…
For 3QFY21, KOTAKB’S profit of Rs 18.5bn, up 16%YOY, was below estimate due to higher credit costs. High slippages &…
Normalisation of tie-up with IBank on health side is key; standalone EPS cut by 2-4% and TP reduced to Rs…
All 13 sectors should see growth in Q3; domestic firms to clock 7-qtr high; margins expected to flatten q-o-q